1643 (excluding title page and references)References: 2 (18 articles included in the Research Topic will have hyperlinks inserted in the final proof)
The Frontiers Research Topic titled Insights in Neuro-Oncology and Neurosurgical Oncology: 2021 published a collection of eighteen articles from May 2021 to March 2022. The topics summarized our understanding, as well key advances, in the field of Neuro-Oncology on a variety of subjects focused on primary central nervous system (CNS) tumors, from biomarkers and diagnostics, model systems, anatomic and surgical considerations, as well as novel approaches to therapeutics. A comprehensive review of brain metastases was also included.
In 2018, Capper et al introduced DNA methylation profiling for CNS tumors, significantly improving our capacity to correctly categorize and diagnose brain tumors in children and adults [1]. More recently, the
In this group of six manuscripts, insights were provided into diverse topics regarding specific neuroanatomic considerations, imaging adjuncts and localized therapies. Skardelly and colleagues assessed extent of resection (EOR) and residual tumor volume in a retrospective multicenter cohort study of adult patients with glioblastoma (GBM). The authors developed a nomogram validated in a separate patient cohort that can be applied to the clinic and incorporated into prospective nonrandomised clinical trials where EOR could bias outcomes with respect to PFS and overall survival (OS). (also referred to as posterior fossa syndrome) of 11% was noted and there were no significant differences between either surgical strategy. The authors advocate for training and application of either neurosurgical approach to tumors localized to the fourth ventricle, individualized to tumor anatomy, infiltration of the vermis and lateral or upwards extension. Li et al discussed advances in the neurosurgical approach to parasellar meningiomas incorporating preoperative imaging and protection of the cerebral arteries and their perforating branches which are often compressed, encased, or rarely invaded by these extra-axial tumors. The authors promote using a bidirectional dissection technique.Gao et al presented an interesting manuscript regarding glioma-associated epilepsy (GAE) and the emerging application of radiomics to neuro-oncology in a cohort of 166 adult patients with frontal gliomas. In addition to identifying 17 specific MR imaging features, the authors also considered the influence of patient age and tumor grade towards an integrated clinical-radiomics predictive model.The application of laser interstitial thermal therapy (LITT) as a minimally-invasive adjunct to surgery was explored by Noh and colleagues. During LITT, there is continuous real-time temperature mapping using magnetic resonance thermometry. The authors studied 17 patients with specific attention to the contribution of signal dropout, an artifact of biopsy, that often precedes LITT. 6 of 17 patients in this group had biopsy with artifact due to the presence of blood or air that affected thresholds of thermal damage at tumor borders.
Two publications included in this article collection regarded GBM tumor heterogeneity and the subventricular zone (SVZ), respectively. Comba et al explored spatiotemporal heterogeneity in glioblastomas in a timely review of the influence of the molecular genetic features of the tumor, the tumor microenvironment (including non-transformed neuronal and glial cells, immune, mesenchymal and stem cells) and dynamic qualities within the tumor itself. The authors discuss the contributions of more recently adopted platforms including machine-learning in histopathology, single cell transcriptomics and spatial transcriptomics. Data acquisition using these technologies will better inform our preclinical models with translational implications, including high throughput drug screening.Beiriger and colleagues compared neural stem/precursor cells (NSC) resident to the adult SVZ and glioma stem cells (GSC) which are both implicated in the pathogenesis of gliomas. The authors review several in vitro and in vivo model systems and include human brain and/or GBM organoids as important emerging model systems to study the contributions of NSC and GSC, thereby reframing our approaches in the laboratory towards improving preclinical translational research.
Two articles discussed insights into the efficacy of tumor treating fields (TTF), an FDA approved treatment adjunct for adults with glioblastoma that is being explored for other treatment indications in children and adults with brain and other solid tumors. The effect of the corticosteroid dexamethasone convened during the early months of the pandemic. Since TTF is administered by a portable device that is used in the home and is not known for additional immunosuppressive effects over and above the intrinsic effects of the tumor itself, the authors advocate that specific patient populations, especially the elderly and those with co-morbidities, may benefit from TTF mediated therapies.
A major focus in neuro-oncology reflects ongoing efforts to advance our understanding and utilization of therapies that harness the immune system. Viral-mediated gene therapies for GBM were reviewed by Li et al. The authors summarize several viral vectors and their potential or current use in viral gene therapy, including retroviruses, lentiviruses, adenoviruses, herpes simplex virus (HSV) and oncolytic viruses; many of these vectors are under active investigation in clinical trials in neuro-oncology.Combined immune checkpoint inhibitor therapy applied to meningeal melanoma, a relatively uncommon tumor entity belonging to the class of primary melanocytic tumors of the CNS, was presented by Burgos et al.Burns and colleagues summarized current efforts in the laboratory and the clinic to use CAR T-cell therapies, already adopted for some hematopoietic malignancies expressing CD19, towards the treatment of very challenging pediatric brain tumors, especially diffuse midline gliomas with Histone
Finally, Li and colleagues provided a comprehensive review of brain metastases (intracranial metastatic disease or IMD) in adults for which the application of improved molecular genetics-based diagnostics, neuroimaging, minimally invasive surgery, novel local therapies, improvements in radiation therapy (stereotactic radiosurgery, hippocampal sparing whole brain radiotherapy, etc.), neurocognitive rehabilitation strategies, and the application of either targeted and/or immunotherapies, offers some hope to these patients with very poor prognoses overall. Specific sections of this review article focus on breast cancer, NSCLC and melanoma given their relative contributions to IMD in adults.
Despite significant progress in neuro-oncology translational and clinical research, we have yet to fully realize the potential of improved diagnostic platforms, advances in therapy from surgery, radiation, other local or systemic therapies, including targeted, viral gene, or immunotherapies. Given the high priority of this combined effort, the neuro-oncology community has mapped out an ambitious agenda towards improving both duration and quality of survival for our pediatric and adult patients with primary or secondary tumors of the central nervous system. However, we will have to continue our collective journey to achieve these worthy goals.


